InflaRx (IFRX) has released an update.
InflaRx’s novel therapeutic candidate, GOHIBIC (vilobelimab), has been chosen by BARDA for a Phase 2 clinical trial aimed at treating Acute Respiratory Distress Syndrome (ARDS), a condition with no approved treatment currently. The study, partnering with PPD Development of Thermo Fisher Scientific, will involve 600 patients across approximately 60 U.S. sites, testing the efficacy and safety of vilobelimab against a placebo, alongside standard care. Vilobelimab, a first-in-class monoclonal anti-C5a antibody, has shown promise in controlling inflammatory responses and organ damage in pre-clinical studies and has been granted an Emergency Use Authorization for COVID-19 treatment in specific severe cases.
For further insights into IFRX stock, check out TipRanks’ Stock Analysis page.
